ClinicalTrials.gg
Sign In
DrugRead study by study

Belzutifan clinical trials

Also written MK-6482, WELIREG™ and PT2977.

studies test it
36
open now
12
in phase 3
6
first study started
2016
ClinicalTrials.gov finds 48 studies for belzutifan. How that becomes 36 here

Every study that search finds has been read, to see whether and how it gives belzutifan. ClinicalTrials.gov counts as of Nov 14, 2026. How drug pages count

  1. 48Found by its intervention search · See all 48 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 42 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
  2. 48Give belzutifan to participants
  3. −2Observe patients on it, or give it outside a trial
  4. −1Use it as a tool: an imaging tracer or a test of drug response
  5. −9Give it beside what is tested
  6. 36Test it: the count on this site

Get an email when these change. Save the belzutifan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Approvals

The first approval found in each region, with its record

United States
13 Aug 2021 · WELIREG · NDA 215383 (FDA, Drugs@FDA)
European Union
12 Feb 2025 · Welireg · EMEA/H/C/005636 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Belzutifan
33
MK-6482, PT2977, WELIREG®
2

Brand

WELIREG™
20

Development codes

MK-6482
21
PT2977
14

Studies by the year they started

35 studies that test it; most in 2021 (6); 1 more planned to start later

Studies that test belzutifan, by start year
YearStudies
20162
20183
20205
20216
20224
20244
20255
20266

By phase

A phase 1/2 study counts in both.

Phase 1
13
Phase 2
19
Phase 3
6
Phase 4
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Carcinoma, Renal Cell
17
von Hippel-Lindau Disease
3
Pheochromocytoma
3
Neoplasms
2
Breast Neoplasms
1
Kidney Failure, Chronic
1
Polycythemia
1
Ovarian Neoplasms
1
Prostatic Neoplasms
1

Who runs them

Industry 24 · Other 12

Merck Sharp & Dohme LLC (20) · Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (4) · Dana-Farber Cancer Institute (2) · M.D. Anderson Cancer Center (2) · Vall d'Hebron Institute of Oncology (1) · Peter MacCallum Cancer Centre, Australia (1) · University of Utah (1) · Longfei Liu，MD (1)

Often tested with

Tested in the same studies.

Pembrolizumab/Quavonlimab MK-1308A (4) · Pembrolizumab (3) · Lenvatinib (2) · Vibostolimab/Pembrolizumab MK-7684A (2) · Favezelimab (2) · Olaparib (1) · Enzalutamide (1) · Abiraterone Acetate (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

New treatments tested with it · 4 most studied

New when their studies opened, with belzutifan beside them; studies of each.

Reaching primary completion within a year · 9

Studies that test belzutifan.

Studies

Open first, then newest update. How each study uses belzutifan has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.

Testing it · 36

See all 36 studies that test belzutifan →

Behind its US label · 5 — the studies the FDA label of WELIREG describes

From the Clinical Studies section of WELIREG (2026-09), as openFDA has it. A study the site does not hold is left out.

Tested on its own · 16 — no other medicine in its arm
Tested with established drugs · 6 — they are given beside it
Tested in a combination · 14 — another drug in the study is under test too
Beside an established treatment under test · 1 — an approved drug, surgery or radiation is what the study tests

Tested with belzutifan: palbociclib 1

Beside a new treatment under test · 6 — a new drug, cell therapy or vaccine is what the study tests

New treatments tested with belzutifan: zanzalintinib 3 · Anti-PD-1/Anti-VEGF Bispecific Antibody MK-2010 1 · 6-(3-(((5-CHLORO-2-METHOXY-3-PYRIDINYL)SULFONYL)AMINO)-2,6-DIFLUOROPHENYL)-N-METHYLIMIDAZO(1,5-A)PYRAZINE-1-CARBOXAMIDE 1 · Allogeneic TGFBR2 KO CAR27/IL-15-expressing NK Cells 1

Beside supportive care · 1 — a supportive treatment or test is studied
Given beside what is tested · 1 — usual care or a partner of the new treatment
Observed · 2 — patients on it are followed, or it is given outside a trial
As a tool · 1 — an imaging tracer or a test of drug response

Codes

What other systems call belzutifan · ClinicalTrials.gg INT001767

  • MeSH (NLM) C000720612belzutifanConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 7K28NB895LBELZUTIFANConfirmed FDA, NLM, Wikidata
  • RxNorm 2567226One source FDA
  • Wikidata Q27456641belzutifanConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C135627BelzutifanOne source FDA
  • DrugBank DB15463One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.

Start the discussion